Evidence map›Paper›PMID 41834901›Full record

ArticleOpen forum infectious diseases2026

Scalability Metrics and Effort Requirements for a Long-Acting Injectable Antiretroviral Treatment Program.

Joshua P Havens, Jennifer O'Neill, Maureen Kubat, Shawnalyn W Sunagawa, Jennifer M Davis, Nada Fadul, Joshua Lechner, Sara H Bares

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Joshua P HavensDivision of Infectious Diseases, University of Nebraska Medical Center, College of Medicine, Omaha, Nebraska, USA.ORCID https://orcid.org/0000-0001-9894-615X
Jennifer O'NeillDivision of Infectious Diseases, University of Nebraska Medical Center, College of Medicine, Omaha, Nebraska, USA.ORCID https://orcid.org/0000-0002-1430-0851
Maureen KubatDivision of Infectious Diseases, University of Nebraska Medical Center, College of Medicine, Omaha, Nebraska, USA.
Shawnalyn W SunagawaDepartment of Pharmacy Practice, University of Nebraska Medical Center, College of Pharmacy, Omaha, Nebraska, USA.ORCID https://orcid.org/0009-0005-3068-3732
Jennifer M DavisDivision of Infectious Diseases, University of Nebraska Medical Center, College of Medicine, Omaha, Nebraska, USA.ORCID https://orcid.org/0000-0002-4971-1490
Nada FadulDivision of Infectious Diseases, University of Nebraska Medical Center, College of Medicine, Omaha, Nebraska, USA.ORCID https://orcid.org/0000-0001-5022-9063
Joshua LechnerNebraska Medicine, Omaha, Nebraska, USA.ORCID https://orcid.org/0009-0000-4521-4967
Sara H BaresDivision of Infectious Diseases, University of Nebraska Medical Center, College of Medicine, Omaha, Nebraska, USA.ORCID https://orcid.org/0000-0002-2130-2505

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Implementation of a long-acting injectable antiretroviral treatment program requires substantial multidisciplinary effort, particularly for program coordination, coverage/billing, and patient support/retention. As our program scaled to 113 patients over 2.5 years, a total of 2.25 full-time equivalents were required. Despite operational demands, clinical outcomes were favorable, supporting real-world feasibility and scalability.

Indexed as

cabotegravir/rilpivirineimplementationlong-acting injectable ART

Identifiers

PMID41834901
PMCPMC12981548

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.